The precise control of light–matter interactions has emerged as a transformative approach in computational pharmacology, offering unprecedented opportunities to accelerate drug discovery. This study presents an AI-driven Light-Spectrum Optimization framework that dynamically adjusts photonic wavelengths during molecular simulations to enhance energy precision, optimize interaction pathways, and improve candidate selection efficiency. Building upon the Photonically-Assisted AI Drug Design Pipeline (PAI-DDP) established in previous studies, this work introduces adaptive spectral modulation as a core mechanism: rather than relying on fixed wavelengths, the system continuously analyzes photonic feedback and uses deep learning algorithms to optimize spectral parameters in real time. Preliminary results indicate a substantial improvement in simulation accuracy, including enhanced prediction of molecular binding affinities, reduced energy discrepancies, and accelerated screening cycles. The adaptive spectrum approach achieves a significant reduction in computational time—by more than 85%—compared to traditional fixed-wavelength photonic simulations. These findings highlight the potential of intelligent light control integrated with AI to redefine computational drug discovery workflows, enabling faster, more precise, and energy-efficient design of therapeutic molecules. This work lays the foundation for the next generation of self-optimizing, photonically-driven drug design platforms capable of responding dynamically to complex molecular landscapes.